^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR E709_T710delinsD

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
1year
Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma. (PubMed, Eur J Case Rep Intern Med)
When EGFR mutation is suspected, complete DNA sequencing of exons 18 to 21 should be carried out and we suggest that afatinib should be the first-line treatment for exon 18 delE709_T710insD-mutated advanced lung adenocarcinomas. Rare EGFR gene mutations are not detected by standard diagnostic kits.DNA sequencing is required to diagnose rare mutations of the EGFR gene.delE709_T710insD-mutated stage IV lung adenocarcinomas respond to afatinib.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 18 mutation • EGFR E709_T710delinsD • EGFR delE709_T710insD
|
Gilotrif (afatinib)
almost2years
[VIRTUAL] Neratinib Efficacy in Patients with EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Findings from the SUMMIT Basket Trial (IASLC-TTLC 2021)
Loperamide prophylaxis (first 8 weeks) was mandatory. Meaningful neratinib activity, regardless of single or complex G719X mutation, was seen in TKI-pretreated NSCLC patients with EGFR exon 18 mutations. ORR and mPFS appear better than previously reported for other EGFR TKIs in TKIrefractory patients. The neratinib SUMMIT trial continues to enroll EGFR exon 18-mutant NSCLC patients.
Clinical • Pan tumor
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M • EGFR G719X • EGFR S768I • EGFR exon 18 mutation • EGFR E709_T710delinsD • EGFR delE709_T710insD
|
Nerlynx (neratinib) • loperamide